CJC-1295 + Ipamorelin

Lyochem buyer fit

Overview

This blend combines two GH-axis peptides that engage separate receptors and converge on somatotroph GH output: CJC-1295 (no-DAC, the Modified GRF 1-29 form) supplies the GHRH-receptor signal that mirrors hypothalamic GHRH, while Ipamorelin supplies the selective GHSR (ghrelin-receptor) signal that mirrors the ghrelin arm. Because the two inputs add together, the pairing yields GH release well above what either peptide reaches alone at matched single doses — the synergy being the whole point of formulating them together, which is why it ranks among the most-cited dual-pathway preparations in research use. Lyochem supplies the CJC-1295 + Ipamorelin blend as a co-lyophilized reference vial certified to ≥99.0% HPLC per component. The default fill is a 1:1 mass ratio (5+5 mg in a 10 mg vial), with 2+5, 5+10, 10+10 and larger totals available through Lyochem's custom-synthesis programme. We co-lyophilize rather than mix in solution because both peptides are short-lived and the freeze-dried state fixes the ratio at the lyophilization step; each release packet reports the two component purities separately plus the measured ratio in the vial actually shipped.

Applications & buyer fit

Specifications

CAS

(blend)

Purity (HPLC)

≥ 99.0% per component

Strength

10 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 30 minutes

MOQ

On request

Lead time

10–18 days

Storage

2–8°C, protect from light

Documentation available on request

• Lot-specific Certificate of Analysis (CoA)
• RP-HPLC chromatogram with peak integration
• ESI-MS identity confirmation (±0.5 Da)
• Sequence verification by LC-MS/MS
• Water content by Karl Fischer
• SDS / MSDS
• Counter-ion analysis (acetate vs TFA)
• Stability at −20 °C across 12 months
• Solubility in BAC water / PBS reconstitution

Independent analytical report

Product- and strength-matched first-page previews are shown separately from the Batch COA. Contact sales with the report number for the complete high-resolution file.

Third-party testView report record →

CJC-1295 + Ipamorelin

5 + 5 mg · HPLC / MS

CJCIPA510-20260814S6492

Third-party testing in Tianjin

Independent HPLC and mass-spectrometry reports from Qorix , the professional, authoritative third-party analytical laboratory at tjqxgd.com, affiliated with the Tianjin International Joint Academy of Biomedicine.

Regulatory note

Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form, not labelled for human administration — Lyochem's GH-axis lots are scoped to research workflows only. Buyers studying somatotropic pharmacology should specify the counter-ion form (acetate by default) and any pulse-vs-sustained study design notes at quote stage.

Selected literature

1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
2. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416.
3. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
4. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534.
5. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53.
6. Sigalos JT, Pastuszak AW, Allison A, Ohlander SJ, Herati A, Lindgren MC, Lipshultz LI. Growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels. Am J Mens Health. 2017;11(6):1752-1757.

Frequently asked questions